Does Breast Surgery Type Alter Incidental Axillary Irradiation? A Dosimetric Analysis of the "Sentinel Envahi et Randomisation du Curage" SERC Trial.

axillary lymph nodes breast cancer mastectomy radiotherapy

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
19 Mar 2024
Historique:
received: 06 02 2024
revised: 02 03 2024
accepted: 11 03 2024
medline: 28 3 2024
pubmed: 28 3 2024
entrez: 28 3 2024
Statut: epublish

Résumé

An incidental axillary dose of adjuvant radiotherapy using tangential beams is usually given after breast-conserving surgery for breast cancer. The goal of this sub-study was to evaluate this incidental dose in the setting of post-mastectomy radiotherapy (PMRT) according to two different radiotherapy techniques. Patients participating in a randomized SERC trial who received PMRT in a single center were included. We collected the incidental axillary dose delivered to the Berg level 1 using different dosimetric parameters and compared two techniques using Student's We analyzed radiotherapy plans from 52 patients who received PMRT from 2012 to 2021. The mean dose delivered to the Berg level 1 was 37.2 Gy. It was significantly higher with VMAT than with 3D-CRT-43.6 Gy (SD = 3.1 Gy) versus 34.8 Gy (SD = 8.6 Gy) On the Berg level 1, PMRT gives a dose at least equivalent to the one given by post-breast-conserving surgery radiotherapy, making it possible to limit completion axillary lymph node dissections in select pN1a patients treated with a mastectomy. Modern radiotherapy techniques like VMAT tend to increase this incidental dose.

Sections du résumé

BACKGROUND BACKGROUND
An incidental axillary dose of adjuvant radiotherapy using tangential beams is usually given after breast-conserving surgery for breast cancer. The goal of this sub-study was to evaluate this incidental dose in the setting of post-mastectomy radiotherapy (PMRT) according to two different radiotherapy techniques.
METHODS METHODS
Patients participating in a randomized SERC trial who received PMRT in a single center were included. We collected the incidental axillary dose delivered to the Berg level 1 using different dosimetric parameters and compared two techniques using Student's
RESULTS RESULTS
We analyzed radiotherapy plans from 52 patients who received PMRT from 2012 to 2021. The mean dose delivered to the Berg level 1 was 37.2 Gy. It was significantly higher with VMAT than with 3D-CRT-43.6 Gy (SD = 3.1 Gy) versus 34.8 Gy (SD = 8.6 Gy)
CONCLUSIONS CONCLUSIONS
On the Berg level 1, PMRT gives a dose at least equivalent to the one given by post-breast-conserving surgery radiotherapy, making it possible to limit completion axillary lymph node dissections in select pN1a patients treated with a mastectomy. Modern radiotherapy techniques like VMAT tend to increase this incidental dose.

Identifiants

pubmed: 38539532
pii: cancers16061198
doi: 10.3390/cancers16061198
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Camille Nicolas (C)

Department of Radiotherapy, Institut Paoli-Calmettes, 13009 Marseille, France.

Claire Petit (C)

Department of Radiotherapy, Institut Paoli-Calmettes, 13009 Marseille, France.

Agnès Tallet (A)

Department of Radiotherapy, Institut Paoli-Calmettes, 13009 Marseille, France.

Jean-Marie Boher (JM)

Biostatistics and Methodology Unit, Institut Paoli-Calmettes, INSERM (National Institute of Health and Medical Research), IRD (Development Research Institute), Aix Marseille University, 13009 Marseille, France.

Leonel Varela Cagetti (L)

Department of Radiotherapy, Institut Paoli-Calmettes, 13009 Marseille, France.

Veronique Favrel (V)

Department of Radiotherapy, Institut Paoli-Calmettes, 13009 Marseille, France.

Laurence Gonzague Casabianca (L)

Department of Radiotherapy, Institut Paoli-Calmettes, 13009 Marseille, France.

Morgan Guenole (M)

Department of Radiotherapy, Institut Paoli-Calmettes, 13009 Marseille, France.

Hugues Mailleux (H)

Department of Medical Physic, Institut Paoli-Calmettes, 13009 Marseille, France.

Julien Darreon (J)

Department of Medical Physic, Institut Paoli-Calmettes, 13009 Marseille, France.

Marie Bannier (M)

Department of Surgical Oncology, Institut Paoli-Calmettes, CRCM (Research Cancer Centre of Marseille), 13009 Marseille, France.

Monique Cohen (M)

Department of Surgical Oncology, Institut Paoli-Calmettes, CRCM (Research Cancer Centre of Marseille), 13009 Marseille, France.

Laura Sabiani (L)

Department of Surgical Oncology, Institut Paoli-Calmettes, CRCM (Research Cancer Centre of Marseille), 13009 Marseille, France.

Camille Tallet (C)

Faculty of Medical and Paramedical Sciences, Medical School, Aix-Marseille University, 13005 Marseille, France.

Charlene Teyssandier (C)

Faculty of Medical and Paramedical Sciences, Medical School, Aix-Marseille University, 13005 Marseille, France.

Anthony Gonçalves (A)

Department of Medical Oncology, CNRS (National Center of Scientific Research), INSERM (National Institute of Health and Medical Research), Institut Paoli-Calmettes, CRCM (Research Cancer Centre of Marseille), Aix-Marseille University, 13009 Marseille, France.

Alexandre De Nonneville (A)

Department of Medical Oncology, CNRS (National Center of Scientific Research), INSERM (National Institute of Health and Medical Research), Institut Paoli-Calmettes, CRCM (Research Cancer Centre of Marseille), Aix-Marseille University, 13009 Marseille, France.

Leonor Lopez Almeida (L)

Department of Clinical Research, Institut Paoli-Calmettes, 13009 Marseille, France.

Nathan Coste (N)

Department of Clinical Research, Institut Paoli-Calmettes, 13009 Marseille, France.

Marguerite Tyran (M)

Department of Radiotherapy, Institut Paoli-Calmettes, 13009 Marseille, France.

Gilles Houvenaeghel (G)

Department of Surgical Oncology, CNRS (National Center of Scientific Research), INSERM (National Institute of Health and Medical Research), Institut Paoli-Calmettes, CRCM (Research Cancer Centre of Marseille), Aix-Marseille University, 13009 Marseille, France.

Classifications MeSH